Their aberrant expression in malignant SGTs was sporadically reported in MEC, a very poor prognosis tumor, and never reported for oncocytic carcinoma, suggesting the use of AR antagonists in therapeutic strategies for these patients. The gene discussed is AR; the disease is mucoepidermoid carcinoma.